GlassScriptPhysician profile
Jonas A Vanags
NPI 1245474048
$14,880.78
in general payments reported to CMS, 2019-2025
75 companies · $3,539 in 2025
The $3,539 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $1,112 · 2021: $1,951 · 2022: $2,174 · 2023: $2,432 · 2024: $2,561 · 2025: $3,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,480 · Education: $51.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,480.18 |
| Education | $51.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,377.01 | 2020-2025 | Botox, Duopa, Ubrelvy |
| Pfizer INC. | $892.75 | 2021-2025 | |
| Emd Serono, INC. | $807.39 | 2019-2025 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $597.88 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $583.20 | 2019-2022 | |
| Neurelis, INC. | $570.11 | 2020-2025 | Valtoco |
| Sk Life Science, INC. | $568.70 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $532.56 | 2019-2025 | |
| Ucb, INC. | $418.83 | 2022-2025 | Rystiggo, Briviact, Nayzilam |
| Lundbeck LLC | $406.85 | 2021-2025 | Vyepti, Rexulti |
| Genentech USA, INC. | $389.77 | 2020-2025 | Ocrevus Zunovo, Ocrevus |
| Eisai INC. | $387.55 | 2019-2025 | |
| Kyowa Kirin, INC. | $379.10 | 2020-2025 | Nourianz |
| Alexion Pharmaceuticals, INC. | $366.52 | 2019-2025 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $365.37 | 2020-2025 | Ingrezza, Ongentys |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonas Vanags listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.